AbbVie Inc. (ABBV)Â
Trading
Quantity
Profitability
Ownership
Largest Insider Buys in Sector
ABBV Insider Trading Activity
ABBV Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $118,092,073 | 13 | 100 |
Related Transactions
| Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | 0 | $0 | 1 | $3.72M | $-3.72M |
| Buckbee Kevin K | SVP, CONTROLLER | 0 | $0 | 2 | $4.16M | $-4.16M |
| Siatis Perry C | EVP, GC AND SECRETARY | 0 | $0 | 3 | $6.97M | $-6.97M |
| Stewart Jeffrey Ryan | EVP, CHIEF COMMERCIAL OFFICER | 0 | $0 | 1 | $10.54M | $-10.54M |
| RICHMOND TIMOTHY J. | EVP, CHIEF HR OFFICER | 0 | $0 | 2 | $10.54M | $-10.54M |
| GONZALEZ RICHARD A | EXECUTIVE CHAIRMAN OF BOARD | 0 | $0 | 4 | $82.16M | $-82.16M |
About AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Insider Activity of AbbVie Inc.
Over the last 12 months, insiders at AbbVie Inc. have bought $0 and sold $118.09M worth of AbbVie Inc. stock.
On average, over the past 5 years, insiders at AbbVie Inc. have bought $414,455 and sold $92.99M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 750 shares for transaction amount of $51,750 was made by Durkin Brian L (VP, Controller) on 2020‑03‑30.
List of Insider Buy and Sell Transactions, AbbVie Inc.
| 2025-03-03 | Sale | GONZALEZ RICHARD A | director | 6,168 0.0003% | $210.53 | $1.3M | +0.13% | |
| 2025-03-03 | Sale | RICHMOND TIMOTHY J. | EVP, CHIEF HR OFFICER | 21,250 0.0012% | $210.45 | $4.47M | +0.13% | |
| 2025-03-03 | Sale | Siatis Perry C | EVP, GC AND SECRETARY | 18,008 0.001% | $210.00 | $3.78M | +0.13% | |
| 2025-02-28 | Sale | GONZALEZ RICHARD A | director | 92,460 0.0052% | $205.11 | $18.96M | +1.27% | |
| 2025-02-28 | Sale | Siatis Perry C | EVP, GC AND SECRETARY | 9,892 0.0006% | $206.30 | $2.04M | +1.27% | |
| 2025-02-26 | Sale | RICHMOND TIMOTHY J. | EVP, CHIEF HR OFFICER | 29,917 0.0017% | $202.90 | $6.07M | +4.26% | |
| 2025-02-26 | Sale | Buckbee Kevin K | SVP, CONTROLLER | 18,944 0.0011% | $203.41 | $3.85M | +4.26% | |
| 2025-02-20 | Sale | Siatis Perry C | EVP, GC AND SECRETARY | 5,778 0.0003% | $197.90 | $1.14M | +5.92% | |
| 2024-12-16 | Sale | Buckbee Kevin K | SVP, CONTROLLER | 1,800 0.0001% | $172.24 | $310,032 | +8.16% | |
| 2024-08-05 | Sale | GONZALEZ RICHARD A | EXECUTIVE CHAIRMAN OF BOARD | 66,500 0.0038% | $186.52 | $12.4M | +4.67% | |
| 2024-07-17 | Sale | GONZALEZ RICHARD A | EXECUTIVE CHAIRMAN OF BOARD | 282,845 0.016% | $175.00 | $49.5M | +9.10% | |
| 2024-03-20 | Sale | Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | 21,082 0.0012% | $176.30 | $3.72M | +3.30% | |
| 2024-03-18 | Sale | Stewart Jeffrey Ryan | EVP, CHIEF COMMERCIAL OFFICER | 58,949 0.0033% | $178.79 | $10.54M | +1.92% | |
| 2024-03-01 | Sale | RICHMOND TIMOTHY J. | EVP, CHIEF HR OFFICER | 75,680 0.0042% | $177.27 | $13.42M | +1.12% | |
| 2024-02-29 | Sale | Michael Robert A. | PRES & CHIEF OPERATING OFFICER | 68,879 0.0039% | $176.45 | $12.15M | +2.76% | |
| 2024-02-29 | Sale | Siatis Perry C | EVP, GC AND SECRETARY | 9,891 0.0006% | $177.39 | $1.75M | +2.76% | |
| 2024-02-29 | Sale | Buckbee Kevin K | SVP, CONTROLLER | 5,144 0.0003% | $176.65 | $908,688 | +2.76% | |
| 2024-02-28 | Sale | GONZALEZ RICHARD A | CHAIRMAN OF THE BOARD AND CEO | 138,616 0.0078% | $177.27 | $24.57M | +1.63% | |
| 2024-02-23 | Sale | Siatis Perry C | EVP, GC AND SECRETARY | 13,753 0.0008% | $177.51 | $2.44M | +1.39% | |
| 2024-02-23 | Sale | Reents Scott T | EVP, CHIEF FINANCIAL OFFICER | 14,140 0.0008% | $177.44 | $2.51M | +1.39% |
Insider Historical Profitability
| GONZALEZ RICHARD A | director | 388929 0.022% | $82.36M | 0 | 25 | |
| Stewart Jeffrey Ryan | EVP, CHIEF COMMERCIAL OFFICER | 60941 0.0035% | $12.91M | 1 | 8 | +37.98% |
| Donoghoe Nicholas | EVP, CHIEF BUS/STRAT OFFICER | 55903 0.0032% | $11.84M | 1 | 2 | +35.4% |
| Buckbee Kevin K | SVP, CONTROLLER | 11496 0.0007% | $2.43M | 0 | 3 | |
| RICHMOND TIMOTHY J. | EVP, CHIEF HR OFFICER | 6130 0.0003% | $1.3M | 0 | 24 | |
| Siatis Perry C | EVP, GC AND SECRETARY | 4619 0.0003% | $978,165.63 | 0 | 8 | |
| SALEKI-GERHARDT AZITA | EVP, CHIEF OPERATIONS OFFICER | 243944 0.0138% | $51.66M | 0 | 19 | |
| Schumacher Laura J | Vice Chairman | 213003 0.0121% | $45.11M | 1 | 14 | +27.78% |
| CHASE WILLIAM J | EVP, Finance & Administration | 169552 0.0096% | $35.91M | 1 | 7 | +28.08% |
| SEVERINO MICHAEL | Vice Chairman | 152103 0.0086% | $32.21M | 0 | 7 | |
| ALBAN CARLOS | Vice Chairman | 114899 0.0065% | $24.33M | 0 | 9 | |
| LEONARD JOHN M. | SVP, Chief Scientific Officer | 107320 0.0061% | $22.73M | 0 | 2 | |
| Michael Robert A. | PRES & CHIEF OPERATING OFFICER | 98645 0.0056% | $20.89M | 0 | 6 | |
| HURWICH THOMAS A. | VP, Controller | 67276 0.0038% | $14.25M | 0 | 7 | |
| Gosebruch Henry O | EVP, Chief Strategy Officer | 41623 0.0024% | $8.81M | 1 | 6 | +30.68% |
| TILTON GLENN F | director | 39735 0.0023% | $8.41M | 1 | 0 | <0.0001% |
| Strom Carrie C | 37921 0.0021% | $8.03M | 0 | 4 | ||
| AUSTIN ROXANNE S | director | 34483 0.002% | $7.3M | 4 | 3 | +31.05% |
| Sorg Elaine K. | SVP, US COMMERCIAL OPERATIONS | 35330 0.002% | $7.48M | 0 | 10 | |
| Reents Scott T | EVP, CHIEF FINANCIAL OFFICER | 27065 0.0015% | $5.73M | 0 | 3 | |
| Durkin Brian L | VP, Controller | 19094 0.0011% | $4.04M | 3 | 3 | +36.78% |
| RAPP EDWARD J | director | 2875 0.0002% | $608,838.75 | 5 | 0 | +17.89% |
| WADDELL FREDERICK H | director | 2000 0.0001% | $423,540.00 | 1 | 0 | +22.11% |
Historical Insider Profitability vs. Competitors
$364,217,072 | 28 | 9.11% | $20.41B | |
$6,077,160 | 24 | 3.21% | $391.98B | |
$1,922,773,492 | 23 | 18.03% | $771.17B | |
AbbVie Inc. (ABBV) | $28,542,809 | 19 | 26.40% | $373.85B |
$23,029,445 | 18 | 9.34% | $119.75B | |
$17,024,470 | 16 | 4.30% | $238.89B | |
$1,995,978 | 16 | -0.53% | $145.76B | |
$3,170,734 | 10 | 3.98% | $168.53B | |
$3,933,798 | 8 | 12.50% | $138.78B | |
$252,679 | 2 | 0.47% | $3.95B |
ABBV Institutional Investors: Active Positions
| Increased Positions | 1,893 | +53.38% | 78M | +6.13% |
| Decreased Positions | 1,573 | -44.36% | 62M | -4.87% |
| New Positions | 372 | New | 18M | New |
| Sold Out Positions | 141 | Sold Out | 1M | Sold Out |
| Total Postitions | 3,866 | +9.02% | 1B | +1.26% |
ABBV Ownership Change vs Market
Institutional Investor Ownership
| Vanguard Group Inc | $36.18M | 9.81% | 173.07M | +1M | +0.83% | 2024-12-31 |
| Blackrock, Inc. | $29.69M | 8.05% | 142.04M | +6M | +4.46% | 2024-12-31 |
| State Street Corp | $16.64M | 4.51% | 79.62M | +553,552 | +0.7% | 2024-12-31 |
| Jpmorgan Chase & Co | $10.82M | 2.93% | 51.76M | -549,610 | -1.05% | 2024-12-31 |
| Morgan Stanley | $8.3M | 2.25% | 39.69M | +972,313 | +2.51% | 2024-12-31 |
| Geode Capital Management, Llc | $7.76M | 2.11% | 37.14M | +983,888 | +2.72% | 2024-12-31 |
| Capital Research Global Investors | $7.1M | 1.93% | 33.98M | +778,126 | +2.34% | 2024-12-31 |
| Capital International Investors | $5.96M | 1.62% | 28.53M | -8M | -22.44% | 2024-12-31 |
| Charles Schwab Investment Management Inc | $5.73M | 1.55% | 27.44M | +4M | +15.1% | 2024-12-31 |
| Bank Of America Corp /De/ | $5.29M | 1.44% | 25.32M | +4M | +20.93% | 2024-12-31 |